Pharmaceuticals - Community Register

  

Community register of medicinal products for human use


AUTHORISED  

Product information

Invented name: Betmiga   
Auth. number : EU/1/12/809
INN : mirabegron
ATC: Anatomical main group: G - Genito urinary system and sex hormones
Therapeutic subgroup: G04 - Urologicals
Pharmacological subgroup: G04B - Other urologicals, including antispasmodics
Chemical subgroup: G04BD - Urinary antispasmodics
Chemical substance: G04BD12 - Mirabegron
(See WHO ATC Index)
Indication: Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
Marketing Authorisation Holder: Astellas Pharma Europe B.V.
Sylviusweg 62, NL-2333 BE Leiden, Nederland

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
07/01/2013 Centralised - Authorisation EMEA/H/C/2388 (2012)9945 of 20/12/2012
19/02/2013 Centralised - Variation EMEA/H/C/2388/IAin/1/G
Updated with Decision(2014)1249 of 20/02/2014
05/02/2014 Centralised - Variation EMEA/H/C/2388/IAin/10/G
Updated with Decision(2014)1249 of 20/02/2014
24/02/2014 Centralised - Variation (2014)1249 of 20/02/2014
25/04/2014 Centralised - Modification EMEA/H/C/2388/PSUV/7 (2014)2809 of 23/04/2014